Creating advanced biologics for targeted cancer treatment
Development of next-generation biologics programmed with multifunctional synthetic chemistries
This study is working on creating new types of proteins that can be customized to better treat diseases like cancer and multiple sclerosis, making them safer and more effective for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pearl Bio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10823892 on NIH RePORTER |
What this research studies
This research focuses on developing next-generation biologics, specifically cytokine proteins, that can be engineered to improve their effectiveness in treating diseases like cancer and multiple sclerosis. The approach aims to overcome current limitations such as rapid degradation and systemic immune activation by creating multifunctional proteins that can be tailored for better specificity and longer-lasting effects in the body. By utilizing innovative synthetic biology techniques, the goal is to enhance the therapeutic potential of these biologics, making them safer and more effective for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer or other conditions that could benefit from advanced biologic therapies.
Not a fit: Patients with conditions not related to cancer or those who do not respond to biologic therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for cancer and other serious diseases.
How similar studies have performed: Previous research has shown promise in developing biologics with enhanced properties, but this approach aims to address specific challenges that have not been fully resolved in earlier studies.
Where this research is happening
Cambridge, United States
- Pearl Bio, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Chattopadhyay, Souvik — Pearl Bio, INC.
- Study coordinator: Chattopadhyay, Souvik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.